[1]余 勃,许　鹏.加味沙参麦冬汤治疗肺癌患者ＥＧＦＲ － ＴＫＩｓ相关皮疹的临床研究[J].陕西中医药大学学报,2019,(03):112-116.[doi:10.13424/j.cnki.jsctcm.2019.03.029]
　Yu Bo Xu Peng.Clinical Study on Modified Shashen Maidong Decoction in Treating EGFR - TKIs Related Rash in Patients with Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2019,(03):112-116.[doi:10.13424/j.cnki.jsctcm.2019.03.029]
点击复制

加味沙参麦冬汤治疗肺癌患者ＥＧＦＲ － ＴＫＩｓ相关皮疹的临床研究 ()
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2019年03期
页码:
112-116
栏目:
临床研究
出版日期:
2019-05-30

文章信息/Info

Title:
Clinical Study on Modified Shashen Maidong Decoction in Treating EGFR - TKIs Related Rash in Patients with Lung Cancer
文章编号:
2096-1340(2019)03-0112-05
作者:
余 勃;  许　鹏
1.西安市长安区医院,陕西西安710100;2.陕西省中医医院,陕西西安710003
Author(s):
Yu Bo 1 Xu Peng 2
1. Changn District Hospital of Xian, Xian China, 710100; 2. TCM Hospital of Shaanxi, Xiaan China, 710003
关键词:
肺癌; 吉非替尼; ＥＧＦＲ－ＴＫＩｓ相关皮疹; 加味沙参麦冬汤
Keywords:
lung cancer;  gefitinib;  EGFR - TKIs related rash;  modified Shashen Maidong Decoction;  Chinese medicine
分类号:
R275
DOI:
10.13424/j.cnki.jsctcm.2019.03.029
文献标志码:
A
摘要:
目的加味沙参麦冬汤治疗肺癌患者EGFR-TKIs相关皮疹的疗效?方法将43例肺癌患者随机分为对照组及治疗组,两组均予吉非替尼口服,共3个月,对照组治疗过程中可局部外用红霉素软膏,每日2次,连续外用不超过15天?治疗组给予加味沙参麦冬汤中药复方口服治疗,每日1剂?比较两组患者的皮肤毒性反应?生存质量和临床疗效?结果虽然治疗组和对照组治疗1个月后,两组患者的皮疹分级临床疗效比较,差异无统计学意义(P>0.05),但随治疗时间的延长,治疗组皮疹例数?发生率均少于对照组,并且差异有统计学意义(P<0.05);治疗前,对照组和治疗组,两组患者的KPS评分差异无统计学意义(P>0.05),治疗后,两组患者的KPS评分较治疗前均升高(P<0.05),但治疗组患者的KPS评分明显高于对照组,且差异有统计学意义(P<0.05);两组治疗后,治疗组PR患者例数及比率均高于对照组,但差异无统计学意义(P>0.05)?结论加味沙参麦冬汤可以降低吉非替尼的皮肤不良反应的发生率,减轻皮肤毒性,并可提高患者耐受性,改善患者体质评分?
Abstract:
Objective To investigate the curative effect of modified Shashen Maidong Decoction in the treatment of EGFR - TKIs related rash in patients with lung cancer. Methods Forty - three patients with lung cancer were randomly divided into control group and treatment group. Gefitinib was given orally to both groups for 3 months. Erythromycin ointment was applied topically to control group twice a day for no more than 15 days. The treatment group was given orally the compound prescription of modified Shashen Maidong Decoction, one dose a day. The skin toxicity, quality of life and clinical efficacy of the two groups were compared. Results Although there was no significant difference in the clinical efficacy of rash grading between the two groups after one month of treatment ( P > 0. 05) , with the prolongation of treatment time, the number and incidence of rash in the treatment group were less than those in the control group, and the difference was statistically significant ( P < 0. 05) . Before treatment, there was no significant difference in KPS score between the control group and the treatment group ( P > 0. 05) . After treatment, the KPS scores of the two groups were higherthan before ( P < 0. 05) , but the KPS scores of the treatment group were significantly higher than those of the control group ( P < 0. 05) . After treatment, the number and ratio of PR patients in the treatment group were higher than those in the control group, but there was no significant difference ( P > 0. 05) . Conclusion Modified Shashen Maidong Decoction can reduce the incidence of adverse skin reactions of gefitinib, alleviate skin toxicity, improve patient tolerance and patient＇s physique score.

参考文献/References:

[1] Carcereny E, Moran T, Capdevila L, et al. The epider -mal growth factor receptor ( EGRF) in lung cancer[ J] .Transl Respir Med,2015,3: 1.
[2 ] Stintzing S. Management of colorectal cancer [ J] .F1000Prime Rep,2014,6: 108.
[3] Sobin LH, Gospodarowicz MK, Wittekind CH. TNM classificationof malignant tumours [ M] . 7th ed. Hoboken:John Wiley &Sons,2009.
[4]支修益,吴一龙,马胜林,等.原发性肺癌诊疗规范(2011年版)[J].中国肺癌杂志,2012,15(12):677-688.
[5] Chen AP, Setser A, Anadkat MJ, et al. Grading derma -tologic adverse events of cancer treatments: the CommonTerminology Criteria for Adverse Events Version 4. 0[ J] . J Am Acad Dermatol,2012,67( 5) : 1025 -1039.
[6] Eisenhauer EA, Therasse P, Bogaerts J, et al. New responseevaluation criteria in solid tumours: revised RECISTguideline( version 1. 1) [ J] . Eur J Cancer, 2009, 45(2) : 228 -247.
[7] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy asfirst - line treatment for patients with advancedEGFR mutation - positive non - small - cell lung cancer (OPTIMAL, CTONG -0802 ) : amulticentre, open - label,randomised, phase 3 study[ J] . Lancet Oncol, 2011, 12(8) : 735 -742.
[8] Reck M, von Pawel J, Zatloukal P, et al. Overall survivalwithcisplatin - gemcitabine and bevacizumab or placebo asfirst - linetherapy for nonsquamous non - small - cell lungcancer: results from arandomized phase Ⅲ trial ( AVAiL) [ J] . Ann Oncol,2010,21( 9) : 1804 -1809.
[9] Pirker R, Pereira J R, Szczesna A, et al. Cetuximab pluschemotherapy in patients with advanced non - small - celllung cancer( FLEX) : an open - label randomised phaseⅢ trial[ J] . Lancet,2009,373( 9674) : 1525 -1531.
[10] Lichtenberger BM, Gerber PA, Holcmann M, et al. Epi- dermal EGFR controls cutaneous host defense and pre -vents inflammation[ J] . Sci Transl Med, 2013, 5 ( 199) :199ra111.
[11] Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology ofskin toxicity associated with epidermal growth factor re -ceptor ( EGFR ) inhibitors[ J] . Support Care Cancer,2012,20( 5) : 909 -921.
[12] Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clini- cal practice guidelines for the prevention and treatmentofEGFR inhibitor - associated dermatologic toxicities [ J] .Support Care Cancer,2011,19( 8) : 1079 -1095.
[13] Macdonald JB, Macdonald B, Golitz LE, et al. Cutane -ous adverse effects of targeted therapies: Part 1: Inhibi -tors of the cellular membrane[ J] . J Am Acad Dermatol,2015,72( 2) : 203 -218,219 -220.
[14] Curry JL, Torres - Cabala CA, Kim KB, et al. Dermato -logic toxicities to targeted cancer therapy: shared clinicaland histologic adverse skin reactions[ J] . Int J Dermatol,2014,53( 3) : 376 -384.
[15] Sinclair R. Anticipating and managing the cutaneoussideeffects of epidermal growth factor receptor inhibitors[ J] . Asia Pac J Clin Oncol,2014,10 Suppl 1: 11 -17.
[16]孙广仁.中医基础理论[M].北京:中国中医药出版社,2002:74-83.
[17]肖寒,方乃青,申小苏.加减沙参麦冬汤联合化疗治疗Ⅲ?Ⅳ期非小细胞肺癌[J].中国实验方剂学杂志,2011,17(24):203-207.
[18]潘国凤,宋巧玲,吴良村.新加沙参麦冬汤联合放疗治疗中晚期非小细胞肺癌30例临床疗效观察[J].中华中医药杂志,2010,25(6):951-952.
[19]袁国荣,潘智敏.沙参麦冬汤减轻易瑞沙不良反应的临床研究[J].中华中医药学刊,2011,29(4):930-931.

相似文献/References:

[1]王留晏 陈露 张克克.肺癌从脾肾论治体悟[J].陕西中医药大学学报,2019,(01):040.[doi:10.13424/j.cnki.jsctcm.2019.01.014]
[2]李宜鲜 魏华琳.山豆根乙醇提取物对 Lewis 肺癌小鼠的抗肿瘤作用[J].陕西中医药大学学报,2021,(03):086.[doi:10.13424/j.cnki.jsctcm.2021.03.019]
[3]王颖 唐晓男 王会宜 崔艳慧 曹飞 康小红.华蟾素胶囊联合吉非替尼对晚期肺癌患者临床疗效及血清miR-221表达的影响[J].陕西中医药大学学报,2021,(06):084.[doi:10.13424/j.cnki.jsctcm.2021.06.017]
　WANG Ying TANG Xiaonan WANG Huiyi CUI Yanhui CAO Fei KANG Xiaohong.Effect of Cinobufagin Capsule Combined with Gefitinib on Clinical Efficacy and Serum miR221 Expression in Patients with Advanced Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,(03):084.[doi:10.13424/j.cnki.jsctcm.2021.06.017]
[4]田王琪 张蔚桐 汪一凡 郭惠 王育伟.中药多糖通过调控肠道菌群干预肺癌的文献研究[J].陕西中医药大学学报,2023,(02):027.[doi:10.13424/j.cnki.jsctcm.2023.02.005]
　TIAN Wangqi ZHANG Weitong WANG Yifan GUO Hui WANG Yuwei TANG Yuping.Research Progress of Chinese Herbal PolysaccharidesIntervening Lung Cancer by Regulating Intestinal Flora[J].Journal of Shaanxi University of Traditional Chinese Medicine,2023,(03):027.[doi:10.13424/j.cnki.jsctcm.2023.02.005]

更新日期/Last Update: 2019-05-29